SCHEMBL25094282

SCHEMBL25094282

CC(C)(C)c1cc(N2CCOCC2)nc(N2CCOCC2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.64
▸ NPSR1 Q6W5P4 3/20 0.56
▸ HRH4 Q9H3N8 2/20 0.56
▸ PIK3CA P42336 3/20 0.52
▸ MAP3K12 Q12852 1/20 0.52
▸ GAA P10253 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ KDM4E B2RXH2 2/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ THRB P10828 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ MTOR P42345 2/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ ATM Q13315 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ CRHBP P24387 1/20 0.46
▸ CRHR2 Q13324 1/20 0.46
▸ RAF1 P04049 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9003193 0.82 KMT2A (0.76) KMT2ANPSR1HRH4PIK3CAMAP3K12
SCHEMBL13326955 0.78 KMT2A (1.00) KMT2ANPSR1HRH4PIK3CAMAP3K12
SCHEMBL5528147 0.78 PIK3CA (0.47) NPSR1PIK3CAPOLBKDM4EALDH1A1
SCHEMBL9640164 0.78 KMT2A (0.69) KMT2ANPSR1HRH4PIK3CAMAP3K12
SCHEMBL9640988 0.78 KMT2A (0.69) KMT2ANPSR1HRH4PIK3CAMAP3K12
SCHEMBL9639621 0.76 KMT2A (0.67) KMT2ANPSR1HRH4PIK3CAMAP3K12
SCHEMBL22169012 0.76 HTT (0.45) KMT2AHRH4PIK3CAKDM4EALDH1A1
SCHEMBL13166826 0.75 CYP2C19 (0.58) KMT2AGAAALDH1A1SMN1; SMN2LMNA
SCHEMBL1123583 0.75 KMT2A (0.65) KMT2ANPSR1HRH4PIK3CAMAP3K12
SCHEMBL1123990 0.75 KMT2A (0.65) KMT2ANPSR1HRH4PIK3CAMAP3K12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KUMQUAT BIOSCIENCES INC. (US) 2023-05-16 — — US disclosed
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KUMQUAT BIOSCIENCES INC. (US) 2023-05-16 — — US disclosed
US-20230064360-A1 HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2023-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KRAS, NRAS, BRAF KMT2A 4174/4885NPSR1 3380/4885HRH4 1890/4885
US-20230064360-A1 HETEROCYCLES AND USES THEREOF KRAS, HRAS, TP53 KMT2A 2806/4885NPSR1 3358/4885HRH4 2035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback